CD34 and chronic myelogenous leukemia, BCR-ABL1 positive: Interestingly, CD34 cells of TKI sensitive CML patient respond to imatinib by apoptosis but addition of MPA did not increase the apoptotic response (supplementary Figure 5(a)).